ZBIOProShares UltraPro Short Nasdaq Biotechnology
ZBIO Fund Description
The ProShares UltraPro NASDAQ Biotechnology provides -3x daily exposure to a market-cap-weighted index of biotechnology and pharmaceutical companies listed on the NASDAQ.
ZBIO Factset Analytics Insight
ZBIO is the newest inverse play on the NASDAQ Biotechnology Index, this one being -3x the exposure of the daily gains of the index, as opposed to the relatively successful -2x iteration of sister fund BIS. The fund gains its -3x exposure to the index through swap agreements, and rebalances its exposure daily. ZBIO is the second triple-inverse biotech fund, following hot on the heels of Direxion’s LABD, which was launched a month earlier. Like all geared funds that rebalance daily, ZBIO is meant for short-term trading, since compounding effects over the long term could create vast differences from expected returns relative to the index—for good or for ill. Trade this fund with limit orders.
ZBIO CHARTS AND PERFORMANCE
ZBIO Summary Data
ZBIO Portfolio Data
ZBIO Index Data
ZBIO Fund Structure
ZBIO Tax Exposures
ZBIO Factset Analytics Block Liquidity
This measurement shows how easy it is to trade a $1 million USD block of ZBIO. ZBIO is rated a N/A out of 5.